Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugssimplyhealthcare Actimmune Prior Auth Policy Updat…
    Ask Trek AI about this page
    CurrentsimplyhealthcarePolicy Y0114_26_3016727_0000_I_C

    Actimmune (interferon gamma-1b) prior authorization

    Customize your policy alerts

    Sign up for simplyhealthcare Policy Y0114_26_3016727_0000_I_C alerts

    Get alerted when Policy Y0114_26_3016727_0000_I_C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria and coverage details for Actimmune and related specialty products for Simply Healthcare Plans members.

    Policy Summary
    Payersimplyhealthcare
    PolicyActimmune (interferon gamma-1b) prior authorization
    Policy CodePolicy Y0114_26_3016727_0000_I_C
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before initiating Actimmune; failure to obtain PA may result in denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearstandard coverage duration noted for many products
    All medically-accepted indicationsindications stance for Actimmune and listed products
    PA requiredPA indicated for Actimmune and listed specialty drugs
    ~10drugs with PA summaries in this excerpt

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Exclusion
    GLP-1 agents excluded when used for weight loss

    Coverage Criteria (Product-specific)

    PROLASTIN-C Initial Therapy

    PROLASTIN-C covered when documentation meets initial-use criteria

    PROLASTIN-C initial criteria: Verified alpha-1 antitrypsin level ≤ 11 micromol/L (≈80 mg/dL by radial immunodiffusion or 57 mg/dL by nephelometry) AND clinically evident emphysema or COPDalpha-1 antitrypsin ≤ 11 micromol/L

    References ATS/ERS 2003; required medical information: method and numeric value

    PROLASTIN-C Continuation Therapy

    PROLASTIN-C continuation criteria

    PROLASTIN-C continued use: Clinically significant improvement or stabilization in clinical signs and symptoms (examples: decreased exacerbation frequency, slowed FEV1 decline, preservation of CT lung density, or improved symptom burden)clinical improvement or stabilization

    Required for continued coverage; coverage duration 1 year

    ALUNBRIG Initial Therapy

    ALUNBRIG coverage criteria for NSCLC

    ALUNBRIG NSCLC: Documented ALK mutation statusALK mutation positive documentation

    Coverage duration 1 year

    AUGTYRO Initial Therapy

    AUGTYRO coverage criteria for oncology indications

    AUGTYRO molecular requirements: For NSCLC: ROS1 mutation status documented; For solid tumors: NTRK gene fusion status documentedmolecular testing documented

    Coverage duration 1 year

    AUSTEDO Initial and Continuation Therapy

    AUSTEDO criteria summarized

    AUSTEDO tardive dyskinesia initial: DSM-5 confirmed diagnosis of tardive dyskinesia AND at least 30 days of stable exposure to implicated dopamine-blocking agents AND presence of involuntary athetoid or choreiform movements30 days stable exposure

    Continuation requires clinically significant improvement or stabilization on AIMS

    AUSTEDO Huntington's disease: Diagnosis of chorea associated with Huntington's diseasediagnosis documented

    Continuation requires improvement or stabilization in chorea score

    Apokyn Initial Therapy

    Apomorphine (Apokyn) initiation criteria

    Apokyn initiation: For initial use in Parkinson disease, apomorphine must be initiated in conjunction with an antiemetic (excluding 5HT3 antagonist agents)antiemetic use during initiation

    Erectile dysfunction use excluded; coverage duration 1 year

    Arcalyst Initial and Continuation Therapy

    Arcalyst criteria highlights

    Arcalyst DIRA initial: IL1RN mutation status documented AND disease is in remission from prior anakinra treatmentIL1RN mutation status documented

    Prerequisite therapy required for some uses; continuation requires maintenance on stable dose with clinical benefit

    Arcalyst recurrent pericarditis: History of at least two prior pericarditis episodes AND using Arcalyst for treatment or reduction in risk of recurrence≥2 prior episodes

    Continuation requires stable dose and clinical improvement

    AUVELITY Initial Therapy

    AUVELITY criteria highlights

    AUVELITY MDD: For major depressive disorder (MDD), individual must be 18 years of age or older and meet required medical information for indicationage ≥18

    Prior authorization required; coverage duration 1 year

    AUVELITY - Initial

    AUVELITY

    AUVELITY initial: For MDD or agitation associated with dementia due to Alzheimer's disease; for MDD individual is 18 years or older; coverage duration 1 year; all medically-accepted indications

    Prerequisite therapy: No

    AVMAPKI FAKZYNJA - Initial

    AVMAPKI FAKZYNJA CO-PACK

    Ovarian cancer criteria: KRAS mutation status required AND ECOG performance status 0-1

    Coverage duration 1 year

    AYVAKIT - Initial

    AYVAKIT

    Indication-specific requirements: For AdvSM/ISM: platelet count ≥ 50 x 10^9/L documented; For GIST: PDGFRA exon 18 mutation status (including D842V) documentedplatelet ≥50 x 10^9/L for AdvSM/ISM

    Prior authorization required; coverage duration 1 year

    BALVERSA - Initial

    BALVERSA

    mUC requirement: For metastatic urothelial carcinoma (mUC), attestation confirming FGFR3 mutation (written or verbal) is requiredFGFR3 mutation attestation

    Prior authorization required; coverage duration 1 year

    Banzel - Initial

    Banzel (rufinamide)

    Epilepsy/seizure requirement: Diagnosis present AND individual aged ≥1 year AND trial and inadequate response or intolerance to ONE preferred agent (e.g., carbamazepine)age ≥1 year; trial of one preferred agent

    Prior authorization required; coverage duration 1 year

    Bempedoic acid - Initial/Continuation

    Bempedoic acid agents

    Initial use criteria: Individual at high ASCVD risk or with HeFH/primary hyperlipidemia per specified diagnostic criteria AND demonstrated suboptimal LDL-C response to therapy (as defined by <50% reduction when baseline known or LDL-C thresholds if baseline unknown)LDL-C response criteria as specified

    Prior authorization required; continuation requires LDL-C reduction or positive clinical response; coverage duration 1 year

    Benlysta - Initial

    Benlysta (belimumab) IV or SC

    Benlysta initial for SLE: Diagnosis of SLE per ACR criteria with ANA ≥1:80 or anti-dsDNA ≥30 IU/mL AND active disease (SELENA-SLEDAI ≥6) while on current regimen AND disease remains active despite corticosteroid, antimalarial and/or immunosuppressant therapy for ≥30 days AND used in combination with standard therapy (not with other biologics or IV cyclophosphamide)SELENA-SLEDAI ≥6

    Initial authorization 6 months; continuation 1 year; detailed renal criteria apply for lupus nephritis

    Besremi - Initial

    BESREMI

    Besremi: Prior authorization required for indicated use

    Coverage duration 1 year

    Bimzelx - Initial

    BIMZELX (guselkumab) subcutaneous

    Psoriasis requirement: Diagnosis of chronic moderate to severe plaque psoriasis per AAD 2019: BSA ≥3% OR <3% with involvement of sensitive areas or areas significantly impacting daily function; individual aged ≥18 yearsBSA ≥3% or sensitive-area involvement

    Prior authorization required; coverage duration 1 year

    Initial therapy (bimekizumab - psoriasis)

    Covered when ALL of the following are met

    Diagnosis of chronic moderate to severe (extensive or disabling) plaque psoriasis confirmed by AAD 2019: either ≥3% BSA OR <3% BSA involving sensitive areasBSA >= 3% or sensitive-area involvement
    Age: Individual is 18 years of age or older>=18 years
    Prerequisite therapy: Member has tried phototherapy or other systemic therapy (e.g., acitretin, cyclosporine, methotrexate) OR has a contraindication to these therapies

    Applies to psoriasis; other indications have analogous prerequisite therapy requirements

    Continuation therapy

    Covered for continuation when ALL of the following are met

    Prior use: Member has been receiving and is maintained on a stable dose of bimekizumab-bkzxstable dose
    Clinical response: Member has clinically significant improvement or stabilization in clinical signs and symptoms of disease

    Carglumic acid criteria

    Carglumic acid — Initial and continuation criteria

    Initial use: Member has diagnosis of acute hyperammonemia due to NAGS deficiency AND using as adjunctive therapy with other ammonia-lowering therapies OR has chronic hyperammonemia due to NAGS deficiency AND using as maintenance therapy OR is using as adjunctive therapy for acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MA) with adjunctive ammonia-lowering therapies

    Required documentation: diagnosis of NAGS deficiency; coverage duration 1 year

    Continuation use: Clinically significant improvement or stabilization in plasma ammonia level

    Required for continued coverage

    Cosentyx criteria

    Cosentyx — Initial and continuation criteria by indication

    Plaque psoriasis initial: Diagnosis of chronic moderate to severe plaque psoriasis with ≥3% BSA OR <3% BSA involving sensitive areas AND inadequate response or intolerance to phototherapy or systemic therapy (acitretin, cyclosporine, methotrexate) OR contraindication

    Prior authorization required; coverage duration 1 year

    Axial spondyloarthritis (nr-axSpA): Non-radiographic axial spondyloarthritis with objective signs of inflammation AND inadequate response or intolerance to ONE conventional therapy (e.g., NSAIDs) OR contraindication to NSAIDs/DMARDs
    Enthesitis-related arthritis: Moderate to severe ERA AND inadequate response or intolerance to ONE conventional therapy (e.g., NSAIDs or nonbiologic DMARDs) OR contraindication
    Continuation: Clinically significant improvement or stabilization in signs and symptoms AND maintained on a stable dose of Cosentyx

    Tadalafil (BPH) criteria

    Tadalafil for BPH — prior therapy requirement

    Initial: Diagnosis of benign prostatic hyperplasia AND trial and inadequate response or intolerance to TWO of: alfuzosin, doxazosin, silodosin

    Prior authorization required; coverage duration 1 year

    Corlanor criteria

    Corlanor — adult and pediatric criteria

    Adult initial: NYHA class II–IV heart failure AND left ventricular ejection fraction documented AND in normal sinus rhythm AND elevated resting heart rate AND age ≥18

    Coverage duration 1 year

    Pediatric: For pediatric NYHA class II–IV heart failure due to cardiomyopathy, age as specified and indication documentation provided
    Continuation: Clinically significant improvement or stabilization in clinical signs and symptoms

    Cresemba criteria

    Cresemba — antifungal criteria

    Invasive aspergillosis setting and prior therapy: Treatment initiated inpatient and requires continued outpatient treatment for invasive aspergillosis or mucormycosis or organism susceptible to isavuconazonium; for invasive aspergillosis there is inadequate response/intolerance/contraindication to voriconazole or liposomal amphotericin B

    Prior authorization required; coverage duration 1 year

    Invasive mucormycosis: Inadequate response/intolerance/contraindication to amphotericin B required
    Refractory esophageal candidiasis (HIV): HIV-infected individual using to treat esophageal candidiasis refractory to oral itraconazole and/or fluconazole

    Cresemba — Initial/Continuing Therapy

    Covered when coverage criteria and prerequisites are met for isavuconazonium (Cresemba):

    Cresemba coverage criteria: Member is continuing treatment initiated inpatient to outpatient for invasive aspergillosis or mucormycosis or organism susceptible to isavuconazonium; documented inadequate response/intolerance/contraindication to specified antifungals where applicable

    Prerequisite therapy required in some indications; coverage duration 1 year

    Cystagon

    Covered when documentation supports medically-accepted indications:

    Cystagon criteria: Indications consistent with medically-accepted uses; prior authorization required

    Coverage duration 1 year

    Danziten

    Covered when documentation supports medically-accepted indications and required testing:

    Danziten criteria: Indications consistent with medically-accepted uses; required medical information includes Philadelphia chromosome status and specific mutation testing (T315I, Y253H, E255K/V, F359V/C/I or G250E)

    Prior authorization required; coverage duration 1 year

    Daraprim (pyrimethamine)

    Covered when used for specified infectious indications with required combination therapy:

    Daraprim criteria: Pyrimethamine used in combination with leucovorin for indicated infections (e.g., toxoplasmosis) with documentation of indication and combination therapy

    Prior authorization required; coverage duration 1 year

    Darzalex Faspro

    Covered when prior exposure to excluded agents is absent:

    Darzalex FASPRO criteria: Indications consistent with medically-accepted uses AND member has not received daratumumab or another anti-CD38 agent

    Prior authorization required; coverage duration 1 year

    Daurismo

    Covered when medically-accepted indications met with age/comorbidity considerations:

    Daurismo criteria: Indications consistent with medically-accepted uses; document if member is ≥75 years or has comorbidities that preclude intensive induction chemotherapy

    Prior authorization required; coverage duration 1 year

    DHE Nasal Agents

    Covered when migraine treatment sequencing or contraindications documented:

    DHE nasal criteria: Member has trialed and had inadequate response or intolerance to up to TWO oral triptans OR has documented reasons oral triptans are unacceptable (unable to take oral meds, need rapid onset, cannot swallow, intolerance, vascular risk factors)trial of up to 2 oral triptans

    Prior authorization required; coverage duration 1 year

    Diacomit

    Covered when used for Dravet Syndrome with combination therapy and prior response details:

    Diacomit criteria: Diagnosis of seizures associated with Dravet Syndrome AND used in combination with clobazam AND documentation of prior inadequate response as indicated

    Prior authorization required; coverage duration 1 year

    Diazepam (High-Risk Medication)

    Covered when prescriber documents high-risk medication rationale or alternatives:

    Diazepam HRM criteria: Prescriber documents diagnosis AND either (1) if patient >65, prescriber acknowledges HRM status and indicates no adverse effects OR (2) contraindication/clinical reason not to use safer alternatives OR (3) patient age 6 months–64 years

    Prior authorization required; coverage duration 1 year

    Dificid (fidaxomicin)

    Covered when used for medically-accepted indications with short duration:

    Dificid criteria: Indications consistent with medically-accepted uses; prior authorization required

    Coverage duration 30 days

    Dimethyl fumarate - Initial therapy

    Covered when ALL of the following are met

    dimethyl fumarate initial coverage: Individual has a diagnosis of relapsing multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease)

    Prior authorization required; coverage duration 1 year

    Dupixent - Initial therapy criteria (selected indications)

    Covered when indication-specific criteria are met

    asthma criteria: Blood eosinophils ≥150 cells/µL AND 3-month trial with inadequate response or intolerance to combination controller therapy (high‑dose ICS+LABA, leukotriene modifiers, theophylline or oral steroids) OR oral steroid–dependent asthma with inadequate response to high‑dose ICS plus daily oral glucocorticoids; documentation of exacerbation historyeosinophils ≥150 cells/µL

    Dupixent initial 6 months; continuation 1 year

    CRSwNP criteria: Diagnosis confirmed by rhinoscopy, endoscopy, or CT AND recent inadequate response to maintenance intranasal steroid AND trial/inadequate response/intolerance to systemic steroids or sino-nasal surgery

    Initial coverage 6 months; continuation 1 year

    EoE criteria: >=15 intraepithelial eos/hpf AND symptoms of dysphagia AND prior trial of PPI and prior trial of topical/systemic glucocorticoids>=15 eos/hpf

    Duragesic (fentanyl) - Initial and continuation use

    Covered when ALL of the following are met

    eligible diagnoses: Diagnosis of cancer-related pain and/or terminal illness receiving palliative care OR pain requiring daily around-the-clock long-acting opioid therapy

    Provide diagnosis; age ≥2 years for fentanyl patch

    prior therapy and opioid exposure: Inadequate response to one alternative (non-opioid analgesics or immediate‑release opioids) OR contraindication to alternatives AND patient is not opioid‑naïve as defined (current short‑acting opioid use, transition between long‑acting opioids, or specified equianalgesic doses)>=60 mg/day morphine eq or listed equivalents

    Initial 3 months; maintenance 6 months; cancer/terminal/palliative 1 year

    continued use: Attestation that long‑acting opioid therapy provided meaningful improvement in pain/function and that prescriber discussed opioid risks and set treatment goals

    Documentation required for continuation

    Elidel (pimecrolimus) - Use criteria

    Covered when ALL of the following are met

    age and prior therapy: Individual is ≥2 years AND using as second-line therapy for mild to moderate atopic dermatitis AND had trial and inadequate response or intolerance to one topical prescription-strength corticosteroid OR corticosteroid inappropriate due to sensitive area or steroid‑induced atrophy

    Prior authorization required; coverage duration 1 year

    Eligard - Use criteria (prostate cancer)

    Covered when appropriate for medically-accepted indications

    Eligard prostate cancer: Appropriate for locally advanced, recurrent, metastatic, or neoadjuvant use per documentation; exclude clinically localized intermediate‑risk presentations unless specific criteria met

    Prior authorization required; coverage duration 1 year

    EMSAM - Use criteria

    Covered when ALL of the following are met

    EMSAM initial: Individual is 18 years of age or older AND has no known contraindications to MAOI therapyage ≥18

    Prior authorization required; coverage duration 1 year

    EMSAM (selegiline transdermal) — Initial Coverage Criteria

    Covered when ALL of the following are met:

    EMSAM initial: Member has no known contraindications to MAOI use

    Age restriction: individual is 18 years of age or older; prior authorization required

    ENBREL — Initial and Continuation Criteria

    Initial use covered when specified indication-specific severity and prior therapy conditions are met; continuation when improvement or stabilization is documented and member is maintained on a stable dose.

    ENBREL initial general: For chronic moderate to severe plaque psoriasis: BSA ≥3% OR <3% with involvement of sensitive/functional areas; other indications require specified prior therapy failures or contraindications

    Prior authorization required; continuation requires clinical improvement/stabilization; coverage duration 1 year

    ENBREL continuation: Clinically significant improvement or stabilization in signs and symptoms AND maintained on a stable dose of etanercept

    Coverage duration 1 year

    ENDARI (l-glutamine) — Initial and Continuation Criteria

    Covered when ALL of the following are met for initial use:

    ENDARI initial: Diagnosis of sickle cell anemia (HbSS or HbS/β0‑thalassemia) AND at least two sickle cell crises in the prior 12 months

    Member ≥5 years of age; prior authorization required; coverage duration 1 year

    ENDARI continuation: Member experienced a reduction in acute complications of sickle cell disease (e.g., reduction in number of events)

    ENSACOVE — Coverage Criteria

    Covered when ALL of the following are met:

    ENSACOVE NSCLC: For NSCLC, documentation of ALK mutation status is provided

    Prior authorization required; coverage duration 1 year

    EPCLUSA (sofosbuvir-velpatasvir) — Coverage Criteria

    Covered when ALL of the following are met:

    EPCLUSA initial: Documentation of chronic hepatitis C infection including genotype and positive HCV RNA AND baseline evaluation for liver fibrosis

    Prior authorization required; applied consistent with AASLD/IDSA guidance

    EPIDIOLEX — Coverage Criteria

    Covered when ALL of the following are met for seizure indications:

    EPIDIOLEX initial: For Lennox‑Gastaut or Dravet syndrome: inadequate response to two prior antiepileptic drugstrial of two prior AEDs

    Prior authorization required; coverage duration 1 year

    EPO Agents (EPOGEN/PROCRIT/RETACRIT) — Initial and Continuation Criteria

    Initial use covered when ALL of the following are met:

    EPO initial: Baseline hemoglobin <10 g/dL AND adequate baseline iron status (TSAT ≥20% OR ferritin ≥80 ng/mL OR bone marrow adequate iron)Hgb <10 g/dL; TSAT ≥20% or ferritin ≥80 ng/mL

    Indication‑specific requirements apply; prior authorization required

    EPO continuation: Member demonstrates continued need and response with Hgb within specified limits and use of lowest effective ESA doseHgb targets as specified

    Not for use beyond 6 weeks after chemo completion for myelosuppressive chemo‑induced anemia

    ESA perioperative initial criteria

    ESA use for elective, non-cardiac, non-vascular surgery is covered when ALL of the following are met

    ESA perioperative criteria: Baseline Hgb >10 g/dL and ≤13 g/dL AND high risk for perioperative transfusion with significant anticipated blood loss AND baseline iron status adequate (TSAT ≥20% or ferritin ≥80 ng/mL or bone marrow adequate iron)Hgb >10 and ≤13 g/dL; TSAT ≥20% or ferritin ≥80 ng/mL

    Prior authorization required

    Eraxis indications

    Eraxis (anidulafungin) covered when ANY of the following indications are present

    Eraxis indications: Diagnosis of candidemia or certain other Candida infections OR esophageal candidiasis OR transitioning from inpatient to outpatient therapy for organism susceptible to anidulafungin

    Prior authorization required; coverage duration 1 year

    Esbriet (pirfenidone) criteria

    Pirfenidone (Esbriet) initial use covered when ALL of the following are met

    Esbriet initial criteria: Diagnosis of idiopathic pulmonary fibrosis (IPF) with exclusion of other known causes of ILD AND HRCT (with or without lung tissue sampling) confirming IPF AND pulmonary function tests within prior 60 days demonstrating FVC ≥50%FVC ≥50%

    Prior authorization required; coverage duration 1 year; continuation requires clinical improvement or stabilization

    External insulin pumps

    External insulin pump coverage when ALL of the following are met

    External insulin pump criteria: Diagnosis of diabetes mellitus AND individual or caregiver completed comprehensive diabetes education AND requires multiple daily insulin injections AND frequent blood glucose testing/readings

    Age requirements apply (≥2 years for type 1; ≥18 years for type 2); prior authorization required; coverage duration 1 year

    Fasenra (benralizumab) criteria

    Fasenra coverage per indication-specific criteria

    Fasenra for EGPA: Relapsing/refractory EGPA with blood eosinophils >10% of leukocytes or absolute >1000/µL (after excluding other causes) AND presence of two or more EGPA featureseosinophils >10% or >1000/µL

    Age ≥18 for EGPA; prior authorization required

    Fasenra for HES: Trial and inadequate response to oral corticosteroids AND two or more HES flares in past 12 months requiring therapy escalation AND eosinophil count ≥1000/µLeosinophil ≥1000/µL

    Age ≥12 for HES; prior authorization required

    Fasenra for severe eosinophilic asthma: Severe eosinophilic asthma meeting policy criteria (e.g., prior controller therapy trials, exacerbation history) with blood eosinophils ≥150 cells/µL at initiationeosinophils ≥150 cells/µL

    Initial Therapy

    Covered when ALL of the following are met for each indication:

    Severe eosinophilic asthma - Initial: Member is ≥6 years old AND had a 3‑month trial with inadequate response or intolerance to combination controller therapy (high‑dose ICS+LABA, leukotriene modifiers, theophylline or oral steroids) AND has experienced ≥2 exacerbations in prior 12 months requiring systemic steroid use AND has blood eosinophil count ≥150 cells/µLeosinophils ≥150 cells/µL

    Initial approval 6 months; continuation 1 year

    EGPA - Initial: Member is ≥18 years old AND diagnosis of relapsing/refractory EGPA with blood eosinophil >10% or absolute >1000 cells/µL (after excluding other causes) AND presence of two or more EGPA featureseosinophils >10% or >1000 cells/µL

    References Wechsler 2024

    HES - Initial: Member is ≥12 years old AND trial and inadequate response to oral corticosteroids AND ≥2 HES flares in past 12 months requiring escalation of therapy

    Continuation Therapy

    Covered for continuation when therapy has demonstrated clinical benefit:

    Severe eosinophilic asthma - Continuation: Member has clinical improvement evidenced by decreased reliever use, decreased exacerbations, increased percent predicted FEV1 from pretreatment baseline, or reduction in reported asthma‑related symptoms AND continues benralizumab with inhaled corticosteroid–based controller therapyclinical improvement (one or more measures)

    Continuation approval duration: 1 year

    EGPA - Continuation: Member has clinically significant improvement or stabilization in EGPA signs and symptoms while on benralizumab with oral corticosteroid therapyclinical improvement or stabilization
    HES - Continuation: Member has clinically significant improvement or stabilization in signs and symptoms (including decrease/absence of HES flares, improvement in fatigue)clinical improvement or stabilization

    FRUZAQLA - Coverage

    Covered with prior authorization when criteria are met

    FRUZAQLA PA conditions: Prior authorization required; individual is using as indicated; coverage duration 1 year

    Exclusion criteria and prescriber restrictions apply as listed

    GALAFOLD - Initial use

    Covered when ALL of the following are met

    GALAFOLD initial criteria: Diagnosis of Fabry disease defined by complete deficiency or <5% mean normal alpha‑galactosidase A enzyme activity OR GLA gene mutation by sequencing AND amendable GLA variant per HEK‑293 assay AND one or more Fabry‑related signs/symptomsalpha‑galactosidase A activity <5% or GLA mutation

    Prior authorization required; coverage duration 1 year

    GATTEX - Initial use

    Covered when ALL of the following are met

    GATTEX initial criteria: Diagnosis of short bowel syndrome AND patient is dependent on parenteral nutrition (PN) supportPN dependence documented

    Initial coverage listed as 7 months; continuation 1 year; prior authorization required

    GAVRETO - Coverage

    Covered when ALL of the following are met

    GAVRETO criteria: Written or verbal confirmation of RET fusion/rearrangement positive tumor; for NSCLC, patient has not received another RET‑targeted agentRET fusion documented

    Prior authorization required; coverage duration 1 year

    GILENYA (fingolimod) - Coverage

    Covered when ALL of the following are met

    Gilenya prior therapy or high disease activity: Either trial and inadequate response or intolerance to one listed disease‑modifying therapy OR high disease activity despite DMT

    Prior authorization required; coverage duration 1 year

    GILOTRIF - Coverage

    Covered when ALL of the following are met

    Gilotrif NSCLC criteria: For NSCLC, documentation of EGFR mutation status is requiredEGFR mutation documented

    Prior authorization required; coverage duration 1 year

    Glatiramer agents - Coverage

    Covered when ALL of the following are met

    Glatiramer criteria: Individual has relapsing multiple sclerosis (including clinically isolated syndrome, relapsing‑remitting or active secondary progressive disease)

    Prior authorization required; coverage duration 1 year

    GLEEVEc (imatinib) - Coverage

    Covered when ALL of the following are met

    Imatinib required information: For CML/ALL, Philadelphia chromosome (Ph) status documented; for MDS/MPD, PDGFR status documented

    Prior authorization required; coverage duration 1 year

    Gleostine (lomustine) - Coverage

    Covered with prior authorization

    Lomustine PA: Prior authorization required for lomustine (Gleostine)

    Coverage duration 1 year

    GLP-1 agents (liraglutide, semaglutide, dulaglutide, etc.) - Coverage for Type 2 Diabetes

    Covered when ALL of the following are met

    GLP-1 diabetes criteria: Used for Type 2 Diabetes with written documentation verifying diagnosis per glycemic criteria (A1C ≥6.5% OR FPG ≥126 mg/dL OR 2‑hr OGTT ≥200 mg/dL OR symptoms with random glucose ≥200 mg/dL) AND not used for weight lossdiabetes diagnostic thresholds as specified

    Prior authorization required; exclusion for weight‑loss indications; coverage duration 1 year

    GLP agents — Type 2 Diabetes coverage criteria

    Covered when ALL of the following are met

    Diabetes diagnosis verification: Documentation and attestation that diagnosis verified by history of A1C ≥6.5% OR FPG ≥126 mg/dL OR 2‑hr OGTT ≥200 mg/dL OR symptoms with random plasma glucose ≥200 mg/dLsee diagnostic thresholds

    Exclusion: use for weight loss is not covered; prior authorization required

    Gomekli for NF1

    Covered when ALL of the following are met

    NF1 and BSA: Indication: neurofibromatosis type 1 (NF1) with Body Surface Area ≥0.40 m2BSA ≥0.40 m2

    Prior authorization required; coverage duration 1 year

    Hadlima (adalimumab biosimilar) inflammatory indications

    Initial and continuation therapy covered when indication-specific prerequisites are met

    Plaque psoriasis (Hadlima): Patient has ≥3% BSA OR <3% BSA with involvement of sensitive areas AND agent used to reduce signs/symptoms or induce/maintain responseBSA criteria as stated

    Age restrictions apply per indication; prior authorization required

    Other inflammatory diseases: For RA, PsA, AS, CD, UC, JIA, uveitis, HS and others: inadequate response to specified conventional therapies OR contraindication to those therapies; continuation requires improvement or stabilization on stable doseprior therapy failure or contraindication

    Coverage duration 1 year

    Hepsera (adefovir) coverage

    Covered when ALL of the following are met

    Hepsera prior antiviral therapy: Individual has had previous trial and inadequate response or intolerance to an alternative antiviral OR has contraindication to alternativesprior trial required

    Age restriction: ≥12 years; prior authorization required; coverage duration 1 year

    Hernexeos oncology coverage

    Covered when ALL of the following are met

    Hernexeos NSCLC: For NSCLC indication, documentation of HER2 (ERBB2) tyrosine kinase mutation status is requiredmutation status documented

    Prior authorization required; coverage duration 1 year

    High Risk Medications (HRM) prior authorization

    PA required for listed HRM when ALL of the following are met

    Age-based applicability: Prescriber must acknowledge HRM status for individuals >65 and attest that medication benefits outweigh potential risks; individuals ≤64 are not subject to PAage >65

    Coverage duration typically 1 year

    Human Growth Hormone (HGH) coverage criteria

    Covered when ALL applicable, indication-specific criteria are met

    Pediatric idiopathic GHD: Idiopathic GHD: signs/symptoms with growth velocity ≥2 SD below mean or height ≤‑2.25 SD AND subnormal GH response (<10 ng/mL) to 2 stimulation tests; other pediatric indications include neonatal hypopituitarism with low GH, SGA without catch‑up growthGH stimulation <10 ng/mL for children

    Prior authorization required; coverage duration 1 year

    Transitioning adolescent: SMR/Tanner stage ≥4 AND GH therapy stopped ≥1 month with reconfirmation via stimulation testing or other specified criteriaSMR ≥4 or reconfirmation pathways
    Adult GHD: Documented childhood‑onset GHD or hypothalamic/pituitary disease/surgery/radiation/trauma AND subnormal GH responses per adult thresholds OR subnormal response plus additional pituitary deficienciesadult GH thresholds as specified

    Human Growth Hormone — Initial and Continuation Criteria

    Covered when specified diagnostic and clinical criteria are met for pediatric, adolescent transition, and adult GHD

    Pediatric idiopathic GHD initial: Signs/symptoms of GHD AND growth velocity 2 SD below mean OR height 2.25 SD below mean AND subnormal GH response (<10 ng/mL) to 2 GH stimulation testsGH <10 ng/mL on 2 tests
    Transitioning adolescent criteria: SMR/Tanner stage ≥4 AND either reconfirmation testing showing subnormal GH response or known genetic/structural causes
    Adult GHD verification: Documented childhood‑onset GHD or hypothalamic/pituitary disease AND subnormal response to GH stimulation testing per adult thresholdsadult GH thresholds
    Continuation in child:

    Adalimumab (Humira) — Indication-specific criteria

    Covered when indication-specific prior therapy and disease severity criteria are met

    Plaque psoriasis initial: Chronic moderate to severe plaque psoriasis with ≥3% BSA OR <3% BSA involving sensitive/impact areas AND agent used to reduce signs/symptoms or induce/maintain responseBSA ≥3% or <3% with sensitive area involvement

    Age requirements vary by indication; prior authorization required

    RA initial: Inadequate response to methotrexate titrated to maximally tolerated dose OR contraindication to methotrexate

    Prerequisite therapy required

    PsA/AS/CD/PJIA/UC/uveitis/HS: Inadequate response or intolerance to specified conventional therapies OR contraindication; for HS requires Hurley stage II or III

    Continuation requires clinical improvement/stabilization

    Oncology and other specialty agents — biomarker and prior therapy-based coverage

    Covered when specified biomarker/mutation testing and prior therapy criteria are satisfied

    Biomarker‑required oncology agents: Required tumor biomarker or mutation status documented as specified for each agent (examples: HER2/ERBB2, HR/HER2, ROS1, Ph chromosome/T315I, IDH2, RET, PDGFRA) AND prior systemic therapy when requiredbiomarker/mutation documentation

    Prior authorization required; coverage duration commonly 1 year

    imkeldi - Initial Coverage

    Covered when ALL of the following are met (imkeldi):

    imkeldi coverage: Prior authorization required AND assess Philadelphia chromosome (Ph) status for CML/ALL indicationsPh status documented

    Coverage duration 1 year

    INCRELEX - Initial Therapy

    Covered when ALL of the following are met (INCRELEX):

    INCRELEX diagnostic criteria: Height SDS ≤ -3.0 AND Basal IGF‑1 SDS ≤ -3.0 AND normal or elevated GH (>10 ng/mL on stimulation) OR GH gene deletion with neutralizing antibodiesHeight and IGF‑1 SDS thresholds as specified

    Prior authorization required; coverage duration 1 year

    Ingrezza - Initial and Continued Use

    Covered when ALL of the following are met (Ingrezza for tardive dyskinesia):

    Ingrezza TD requirements: DSM‑5 diagnosis with stable medication exposure to dopamine‑blocking agents AND presence of involuntary athetoid or choreiform movements AND patient is ≥18 years oldage ≥18

    For continued use, clinical improvement or AIMS stabilization required; prior authorization required; coverage duration 1 year

    Iressa - NSCLC

    Covered when ALL of the following are met (Iressa/gefitinib):

    Gefitinib (NSCLC): Diagnosis of recurrent, advanced, or metastatic NSCLC AND documented EGFR mutation statusEGFR mutation documented

    Prior authorization required; coverage duration 1 year

    Itovebi - Breast Cancer

    Covered when ALL of the following are met (Itovebi):

    Itovebi breast cancer requirements: Breast cancer biomarker status (IHC, HR, HER2) and PIK3CA‑mutation status documented AND disease progression during adjuvant endocrine therapy or within 12 months of completing adjuvant therapy

    Prior authorization required; coverage duration 1 year

    Itovebi criteria

    Itovebi (oral tablets 3 mg, 9 mg) covered when specified biomarker and timing criteria documented

    Itovebi initial criteria: Documentation of breast cancer IHC (0/1+ or 2+/ISH‑), hormone receptor status, HER2 status, and PIK3CA‑mutation status; progression during adjuvant endocrine treatment within 12 months of completing adjuvant therapy

    Prior authorization required; coverage duration 1 year

    Itraconazole criteria

    Itraconazole covered for medically-accepted indications with indication-specific duration and prerequisite therapy for some tinea infections

    Itraconazole criteria: For onychomycosis: treatment duration limited to 12 weeks. For other indications generally up to 1 year. For certain tinea infections, requires trial and inadequate response or intolerance to at least one prior topical therapy (ciclopirox, clotrimazole, ketoconazole, econazole, or nystatin) or transition from inpatient therapyonychomycosis duration 12 weeks when applicable

    Prior authorization required for specified indications

    IVIG criteria

    IVIG covered for multiple immunologic, autoimmune, hematologic, infectious, neurologic, and transplant-related indications when indication-specific diagnostic and treatment-failure criteria are met.

    Primary/secondary immunodeficiency: Sinopulmonary infections requiring antibiotics with inadequate response to immunodeficiency evaluation AND pre‑treatment serum IgG below age‑adjusted lower limit or >2 SD below mean; exclude renal/GI causes

    Prior authorization required; continuation requires objective clinical improvement; typical coverage 1 year

    Autoimmune/hematologic uses: IVIG for ITP (active bleed or platelet <30,000/µL), fetal alloimmune thrombocytopenia with prior affected pregnancy, isoimmune hemolytic disease of the newborn, and other autoimmune diseases when prior therapies failed or are contraindicated

    Continuation requires objective clinical improvement

    Neurologic and transplant uses: Indications include CIDP, MG, MMN, Lambert‑Eaton, stiff‑person syndrome, and transplant desensitization/antibody‑mediated rejection with guideline/diagnostic confirmation and prior therapy trials as specified

    Prior authorization required; continuation requires demonstrated clinical benefit

    Other specialty drug criteria

    These products require prior authorization with age or diagnosis-specific documentation; coverage durations commonly set to 1 year.

    Jadenu: Deferasirox (Jadenu) requires prior authorization; age restrictions apply for specific diagnoses (e.g., NTDT ≥10 years, chronic iron overload ≥2 years); coverage duration 1 year
    Jakafi (and XR) require prior authorization with coverage duration 1 year

    Specific clinical criteria referenced in product block

    Jaypirca requires prior authorization with coverage duration 1 year

    Specific clinical criteria referenced in product block

    Jynarque: Tolvaptan (Jynarque) requires documentation that adult patient is at risk of rapidly progressing ADPKD consistent with Mayo class IC/ID/IEMayo class IC/ID/IE documentation

    Age ≥18 required; prior authorization required; coverage duration 1 year

    This policy explicitly lists an exclusion for the use of tadalafil‑PAH formulations when prescribed for erectile dysfunction. Prior authorization for tadalafil in the PAH indication still requires documentation of WHO Group 1 pulmonary arterial hypertension with right‑heart catheterization showing: mPAP ≥ 25 mm Hg, PCWP/PAWP/LVEDP ≤ 15 mm Hg, and PVR > 3 Wood units, and WHO functional class II–IV symptoms; however, prescribing the PAH formulation to treat erectile dysfunction is not covered. Coverage duration for approved PAH use is typically 1 year.

    Apomorphine (Apokyn) is excluded from coverage when used for erectile dysfunction. For covered use in Parkinson disease, initial administration must be started in conjunction with an antiemetic (excluding 5‑HT3 antagonist agents) and prior authorization is required; approved treatment durations are generally set to 1 year. The exclusion for ED indicates apomorphine will not be authorized when the indication provided is erectile dysfunction.

    Provider Actions, Prior Authorization & Required Documentation

    Prior Authorization

    Actimmune — prior authorization required

    Prior authorization is required for ACTIMMUNE. Initial approvals are issued with a coverage duration of 1 year and the product is listed for all medically-accepted indications.

    Prior Authorization

    ALECENSA — prior authorization

    ALECENSA requests require prior authorization; coverage duration is listed as 1 year and the product is included under the plan's prior authorization program.

    Prior Authorization

    PROLASTIN‑C — document low A1AT and emphysema/COPD

    PROLASTIN-C prior authorization requires a verified alpha‑1 antitrypsin level ≤ 11 micromol/L (approx. 80 mg/dL by radial immunodiffusion or 57 mg/dL by nephelometry) and documentation of clinically evident emphysema or COPD; continuation requires clinically significant improvement or stabilization.

    Coding & Code Lists

    Bimzelx productsNDCCovered
    BIMZELX SUBCUTANEOUS SOLUTION AUTO-INJECTOR 160 MG/ML, 320 MG/2MLProduct descriptor as listed
    BIMZELX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 160 MG/ML, 320 MG/2MLProduct descriptor as listed
    Bimzelx productsNDCCovered
    SOLUTION PREFILLED SYRINGE 160 MG/ML, 320 MG/2MLProduct descriptor as listed
    Bosulif (bosutinib)mixedCovered
    bosutinibORAL TABLET 100 MG, 400 MG, 500 MG
    BraftovimixedCovered
    BRAFTOVI ORAL CAPSULE 75 MGProduct descriptor as listed
    BrukinsamixedCovered
    BRUKINSA ORAL CAPSULE / TABLETProduct descriptor as listed
    BuphenylmixedCovered
    sodium phenylbutyrate oral powder 3 gm/tspBuphenyl product descriptor
    sodium phenylbutyrate oral tabletBuphenyl product descriptor
    BysantimixedCovered
    BYSANTIProduct and titration packs
    CabometyxmixedCovered
    CABOMETYXProduct descriptor
    CalquencemixedCovered
    CALQUENCE ORAL TABLETProduct descriptor
    CaprelsamixedCovered
    CAPRELSA ORAL TABLET 100 MG, 300 MGProduct descriptor
    Products listed (partial)mixed
    CAPRELSA ORAL TABLET 100 MG, 300 MGProduct listed
    Products listed (partial)mixed
    carglumic acid oral tablet solubleCarglumic acid
    Products listed (partial)mixed
    COSENTYX (300 MG DOSE)Cosentyx product
    COSENTYX SENSOREADY (300 MG)Cosentyx presentation
    COSENTYX SENSOREADY PENCosentyx pen
    COSENTYX SUBCUTANEOUSCosentyx SC
    Products listed (partial)mixed
    CRESEMBA ORALIsavuconazonium oral
    Products Affectedmixed
    CRESEMBA ORALCresemba oral
    Products Affectedmixed
    CYSTAGONCystagon
    Products Affectedmixed
    DANZITENDanziten
    Products Affectedmixed
    pyrimethamineDaraprim (pyrimethamine) oral
    Products Affectedmixed
    DARZALEX FASPRODarzalex Faspro
    Products Affectedmixed
    DAURISMO ORAL TABLET 100 MGDaurismo 100 mg
    DAURISMO ORAL TABLET 25 MGDaurismo 25 mg
    Products Affectedmixed
    dihydroergotamine mesylate nasalDHE nasal
    Products Affectedmixed
    DIACOMIT ORAL CAPSULE 250 MGDiacomit 250 mg capsule
    DIACOMIT ORAL CAPSULE 500 MGDiacomit 500 mg capsule
    DIACOMIT ORAL PACKET 250 MGDiacomit 250 mg packet
    DIACOMIT ORAL PACKET 500 MGDiacomit 500 mg packet
    Products Affectedmixed
    DIAZEPAM INTENSOLDiazepam Intensol
    diazepam oral concentrateDiazepam oral concentrate
    diazepam oral solution 5 mg/5mlDiazepam oral solution 5 mg/5ml
    diazepam oral tablet 10 mg, 2 mg, 5 mgDiazepam oral tablets 10/2/5 mg
    Products Affectedmixed
    DIFICIDDificid
    fidaxomicinfidaxomicin
    Covered drug names (examples)NDC|mixedCovered
    DIFICIDfidaxomicin
    Dimethyl fumarate productsNDC|mixedCovered
    dimethyl fumarate 120 mgdelayed release oral capsule 120 mg
    dimethyl fumarate 240 mgdelayed release oral capsule 240 mg
    Dupixent presentationsNDC|mixedCovered
    DUPIXENT 200 mg/1.14 mLsubcutaneous solution auto-injector / prefilled syringe 200 mg
    DUPIXENT 300 mg/2 mLsubcutaneous solution auto-injector / prefilled syringe 300 mg
    Duragesic (fentanyl)NDC|mixedCovered
    fentanyl (Duragesic)transdermal patch
    ElidelNDC|mixedCovered
    pimecrolimus (Elidel)topical cream
    EligardNDC|mixedCovered
    ELIGARDleuprolide acetate depot
    EMSAMNDC|mixedCovered
    EMSAMselegiline transdermal system
    Covered drug productsmixedCovered
    FASENRA PENProduct affected (benralizumab)
    FASENRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.5ML, 30 MG/MLProduct affected (benralizumab formulations)
    Products Affected - Fruzaqlamixed
    FRUZAQLA ORAL CAPSULE 1 MG, 5 MGProduct affected listing (no formal billing codes provided)
    Products Affected - Galafoldmixed
    GALAFOLDProduct affected listing (diagnostic criteria required)
    Products Affected - Gattexmixed
    GATTEXProduct affected listing (SBS indication)
    Products Affected - Gavretomixed
    GAVRETOProduct affected listing (RET fusion positive tumors)
    Products Affected - Gilenyamixed
    fingolimod hclGilenya product listing
    Products Affected - Gilotrifmixed
    GILOTRIFProduct listing (EGFR mutation status required for NSCLC)
    Products Affected - Glatiramer agentsmixed
    glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/mlGlatiramer product listings
    GLATOPA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20Glatopa product listing
    Products Affected - Gleevecmixed
    imatinib mesylate oral tablet 100 mg, 400 mgGleevec product listing
    Products Affected - Gleostinemixed
    lomustineGleostine product listing
    Products Affected - GLP-1 agentsmixed
    liraglutide; OZEMPIC; RYBELSUS; TRULICITYGLP-1 agents product listings (multiple formulations and strengths listed)

    Definitions & Key Clinical Thresholds

    inv-171: EGPA eosinophil threshold — >10% or absolute >1000 cells/µL
    EGPA eosinophil criterion>10% of leukocytes OR absolute eosinophil count >1000 cells/µL (after excluding other causes)
    ContextRequired for initial EGPA coverage (Wechsler 2024) and must be present with ≥2 EGPA features
    Related requirementDocumentation must exclude other causes of eosinophilia (hypereosinophilic syndromes, neoplastic disease, parasitic infection)
    inv-172: Eosinophil thresholds — >=150 cells/µL for severe eosinophilic asthma; >10% or >1000 cells/µL for EGPA
    Severe eosinophilic asthma>= 150 cells/µL blood eosinophils at initiation (after excluding other causes)
    EGPA>10% of leukocytes OR absolute >1000 cells/µL (after excluding other causes)

    Step Therapy Requirements

    Step therapy requirementDetails
    Required prior to coverage of listed AED agents
    Trial and inadequate response or intolerance to ONE listed preferred antiepileptic agent (e.g., carbamazepine, levetiracetam IR, lamotrigine IR, valproate, topiramate, etc.) or documentation that the preferred agent is not FDA‑approved for the prescribed indication
    Step therapy requirementDetails
    Prerequisite therapy required for some Arcalyst indications
    For initial DIRA use: documentation of IL1RN mutation status and disease in remission from prior anakinra treatment; prerequisite therapy indicated for specified Arcalyst indications
    Step therapy requirementDetails
    Trial of one preferred agent required before authorization
    Individual must have had a trial and inadequate response or intolerance to ONE preferred agent (examples listed per product entry) prior to authorization (e.g., rufinamide requires failure of one preferred AED)
    Step therapy requirementDetails
    Trial and failure/intolerance of specified conventional therapies required prior to biologic approval unless contraindicated
    For biologic agents (examples: psoriasis, AS, nr-axSpA, HS), member must have had inadequate response or intolerance to listed conventional therapies (phototherapy or systemic agents for psoriasis; NSAIDs or nonbiologic DMARDs for AS/nr-axSpA; oral antibiotics for HS) unless there is documented contraindication
    Step therapy requirementDetails
    Required prior to tadalafil (5 mg) for BPH
    Member must have trialed and had an inadequate response or intolerance to TWO of the following: alfuzosin, doxazosin, silodosin prior to approval of tadalafil 5 mg for BPH
    Step therapy requirementDetails
    Required prior to Cosentyx for plaque psoriasis
    For plaque psoriasis initial use, member must have inadequate response or intolerance to phototherapy or other systemic therapy (e.g., acitretin, cyclosporine, methotrexate) or documented contraindication to these therapies
    Step therapy requirementDetails
    Trial of up to two oral triptans required prior to DHE nasal unless contraindicated
    Member must have trialed and had inadequate response or intolerance to up to TWO oral triptan agents (almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan) unless oral triptans are unacceptable for documented clinical reasons (unable to take oral meds, rapid onset required, unable to tolerate oral triptans, or vascular risk factors)
    Step therapy requirementDetails
    Trial documented prior therapy failure or intolerance before approval
    For indication-specific agents (example Dupixent), initial use requires documented failure or intolerance to specified prior therapies (e.g., 3-month trial of combination controller therapy for severe eosinophilic asthma or prior topical/systemic therapies for dermatologic indications) as outlined in product criteria
    Step therapy requirementDetails
    Required prior/concurrent trials of conventional therapies or documented contraindication
    ENBREL initial use requires failure or intolerance to one or more conventional therapies (e.g., methotrexate titrated to maximally tolerated dose for RA; phototherapy or one systemic agent for plaque psoriasis) or documented contraindication to those therapies
    Step therapy requirementDetails
    Documentation of trials for at least two antiepileptic drugs
    EPIDIOLEX initial therapy for Lennox-Gastaut or Dravet syndrome requires inadequate response to two prior antiepileptic drugs documented in the medical record prior to authorization
    Step therapy requirementDetails
    Prior therapy required before Fasenra for HES
    For HES initial use, member must have had a trial and inadequate response to oral corticosteroids and have experienced two or more HES flares in the past 12 months requiring escalation of therapy; eosinophil thresholds and age requirements apply
    Step therapy requirementDetails
    Trial of high-dose ICS+LABA prior to benralizumab for asthma
    For severe eosinophilic asthma, initial approval requires a 3-month trial with inadequate response or intolerance to high‑dose inhaled corticosteroid plus long‑acting beta2‑agonist (or other listed controller therapies such as leukotriene modifiers, theophylline or oral corticosteroids) and documented exacerbation history; blood eosinophil threshold applies
    Step therapy requirementDetails
    Documentation of prior inadequate response or intolerance — recurring step requirement
    Many biologic and specialty agents require documented inadequate response or intolerance to specified conventional therapies (examples include MTX for RA, phototherapy/systemic agents for psoriasis, NSAIDs/DMARDs for AS) or documentation of contraindication prior to approval
    Step therapy requirementDetails
    Failure or intolerance to specified conventional therapy required before approval
    For Humira (adalimumab) indications (RA, PsA, AS, psoriasis, PJIA, UC, uveitis, HS, CD), prerequisite therapy requirements include failure or intolerance to specified conventional therapies (e.g., methotrexate for RA; phototherapy or one systemic therapy for psoriasis; NSAIDs or nonbiologic DMARDs for AS) unless contraindicated
    Step therapy requirementDetails
    No prerequisite therapy required for INCRELEX
    INCRELEX (mecasermin) initial use: no prerequisite therapy required; eligibility is based on primary IGF‑1 deficiency diagnostic criteria documented in the record
    Step therapy requirementDetails
    No prerequisite therapy required for Ingrezza
    Ingrezza initial use for tardive dyskinesia does not require prior pharmacologic step therapies; approval requires DSM‑5 confirmation of TD, documented stable offending medication exposure, presence of involuntary movements, and age ≥18
    Step therapy requirementDetails
    Required for certain tinea indications before itraconazole approval
    For second‑line non‑onychomycosis tinea infections, itraconazole requires prior trial and inadequate response or intolerance to at least one topical therapy (e.g., ciclopirox, clotrimazole, ketoconazole, econazole, or nystatin) before authorization; onychomycosis duration limits also apply
    Step therapy requirementDetails
    Required prior therapies before IVIG initiation for many autoimmune/neurologic indications
    Initial IVIG for specified autoimmune and neurologic diagnoses typically requires prior inadequate response, intolerance, or contraindication to specified alternative therapies (number and type vary by indication) before IVIG initiation; continuation requires objective clinical benefit

    Quantity & Duration Limits

    inv-459: DIFICID (fidaxomicin) — 30 days
    DIFICID quantity limit30 days
    PA requirementPrior authorization required for fidaxomicin; exclusion criteria may apply
    inv-460: dimethyl fumarate — 1 Year
    Dimethyl fumarate duration1 Year
    IndicationRelapsing multiple sclerosis (RMS); prior authorization required
    inv-461: Dupixent — Initial 6 months; Continuation 1 year
    Dupixent initial and continuation durations

    Site of Care Notes

    Note

    Infusion center — not specified

    The document does not specify infusion center site‑of‑care details in this excerpt.

    Note

    Hospital outpatient — inpatient initiation then outpatient continuation for select antifungals

    For certain infections treated with inpatient initiation (e.g., isavuconazonium/Cresemba), the policy requires initial inpatient start with documented reason and allows outpatient continuation under PA.

    Note

    Dupixent — no explicit office/home restriction stated

    No explicit site‑of‑care restriction is stated for Dupixent in this excerpt; subcutaneous administration may occur in office or at home per product labeling.

    Background

    This policy segment provides concise prior authorization (PA) criteria across multiple specialty therapies, emphasizing required diagnostic documentation, biomarker/mutation testing where relevant, and indication‑specific prerequisites. Common elements include: (1) PA required for listed agents with initial approvals commonly issued for 1 year and continuation requiring evidence of clinical benefit; (2) targeted oncology and precision therapies require written or lab verification of tumor biomarkers (examples: ALK, ROS1, NTRK, PDGFRA exon 18, FGFR3, RET) before authorization; (3) biologic and immunomodulatory agents require indication‑appropriate disease severity measures and prior therapy trials or documented contraindications (examples: BSA ≥3% or involvement of sensitive areas for psoriasis; SELENA‑SLEDAI ≥6 for SLE; blood eosinophils ≥150 cells/µL for severe eosinophilic asthma); (4) some metabolic, genetic, and rare disease therapies require enzyme assay or genetic confirmation (examples: alpha‑1 antitrypsin level ≤11 micromol/L for PROLASTIN‑C; alpha‑galactosidase A activity <5% or GLA mutation for GALAFOLD); and (5) several agents specify step‑therapy or prerequisite trials (e.g., trial of up to two oral triptans before DHE nasal agents, trials of conventional systemic or phototherapy prior to certain biologics). The background excerpt summarizes these themes to guide providers on the typical documentation and testing needed to support PA requests across the specialty drug portfolio.

    Policy Summary
    Payersimplyhealthcare
    PolicyActimmune (interferon gamma-1b) prior authorization
    Policy CodePolicy Y0114_26_3016727_0000_I_C
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before initiating Actimmune; failure to obtain PA may result in denial.
    SourceLink
    On This Page
    Coverage Criteria (Product-specific)Provider Actions, Prior Authorization & Required DocumentationCoding & Code ListsDefinitions & Key Clinical ThresholdsStep Therapy RequirementsQuantity & Duration LimitsSite of Care NotesBackground

    Age ≥6 for severe eosinophilic asthma; prior authorization required

    clinical flares ≥2 in 12 months

    Coverage duration 1 year

    Child evaluated AND for children >12 either radiographic evidence that epiphyses have NOT closed OR SMR ≤3
    Continuation: Clinically significant improvement or stabilization AND maintained on stable dose of adalimumab

    Coverage duration 1 year

    Prior Authorization

    ALUNBRIG — provide ALK mutation status

    ALUNBRIG prior authorization for NSCLC requires documentation of ALK mutation status; coverage duration is 1 year.

    Prior Authorization

    Amphetamine salts — prior authorization (1 year)

    Amphetamine‑dextroamphetamine products require prior authorization and are assigned a coverage duration of 1 year; age and prescriber restrictions are referenced in the product entry.

    Prior Authorization

    Ampyra — improvement in ambulation required for renewal

    Dalfampridine (Ampyra) prior authorization requires documentation that the member achieved and sustained improvement in ambulation for renewal; coverage duration is 1 year.

    Prior Authorization

    Apokyn — initiate with antiemetic (no 5‑HT3 antagonists)

    Apomorphine (Apokyn) prior authorization requires that initial use for Parkinson disease be initiated in conjunction with an antiemetic (excluding 5‑HT3 antagonists); erectile dysfunction use is excluded and coverage duration is 1 year.

    Prior Authorization

    Arcalyst — document IL1RN mutation status

    Arcalyst prior authorization for DIRA requires documentation of IL1RN mutation status and that disease is in remission from prior anakinra; continuation requires maintenance on a stable dose with clinical improvement or stabilization.

    Prior Authorization

    Augtyro — provide ROS1 or NTRK molecular testing

    AUGTYRO prior authorization requires molecular testing documentation: ROS1 mutation status for NSCLC and NTRK gene fusion status for solid tumors; coverage duration is 1 year.

    Prior Authorization

    Austedo — DSM‑5 confirmation and stable exposure required

    AUSTEDO prior authorization requires diagnosis‑specific documentation: for tardive dyskinesia a DSM‑5 confirmation, at least 30 days of stable exposure to offending medications, and presence of involuntary movements; continuation requires clinically significant improvement or stabilization on the appropriate scales.

    Prior Authorization

    Auvelity — age ≥18 for MDD; PA required

    AUVELITY prior authorization requires that for major depressive disorder the individual be 18 years of age or older; PA criteria apply and coverage duration is 1 year.

    Prior Authorization

    AUVELITY — prior authorization and 1‑year duration

    AUVELITY prior authorization: initial approval requires meeting the product's PA criteria including the age restriction (MDD ≥18 years); coverage duration is 1 year.

    Prior Authorization

    AVMAPKI FAKZYNJA — KRAS and ECOG 0–1 required

    AVMAPKI FAKZYNJA co‑pack prior authorization requires documentation of KRAS mutation status and ECOG performance status 0–1 for the ovarian cancer indication; coverage duration is 1 year.

    Prior Authorization

    AYVAKIT — platelet threshold and PDGFRA mutation required

    AYVAKIT prior authorization requires a platelet count ≥50 x 10^9/L for AdvSM/ISM indications and PDGFRA exon 18 mutation status (including D842V) for GIST indications; coverage duration is 1 year.

    Prior Authorization

    Balversa — attestation of FGFR3 mutation required

    BALVERSA prior authorization for metastatic urothelial carcinoma requires a written or verbal attestation confirming FGFR3 mutation; coverage duration is 1 year.

    Prior Authorization

    Banzel — trial of one preferred agent required

    Banzel (rufinamide) prior authorization requires diagnosis documentation, age ≥1 year, and a trial with inadequate response or intolerance to ONE preferred agent (e.g., carbamazepine) prior to approval; coverage duration is 1 year.

    Prior Authorization

    Bempedoic acid agents — lipid‑lowering prerequisites

    NEXLETOL/NEXLIZET (bempedoic acid) prior authorization requires documentation of high ASCVD risk or HeFH/primary hyperlipidemia and suboptimal LDL‑C response to therapy; continuation requires LDL‑C reduction or positive clinical response and coverage is typically 1 year.

    Documentation Required

    Benlysta — strict SLE diagnostic, lab, and activity documentation

    BENLYSTA prior authorization (IV or SC) requires SLE diagnosis per ACR criteria with lab verification (positive ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL), active disease demonstrated by SELENA‑SLEDAI ≥6 while on current therapy, ≥30 days of standard therapy, and use in combination with standard therapy; initial authorization 6 months, continuation 1 year.

    Prior Authorization

    Besremi — prior authorization (1 year)

    BESREMI requires prior authorization and is assigned a coverage duration of 1 year.

    Prior Authorization

    Bimzelx — AAD 2019 criteria and age ≥18

    BIMZELX (guselkumab) prior authorization requires confirmation of chronic moderate to severe plaque psoriasis per AAD 2019 (BSA ≥3% or <3% with sensitive/impact areas) and the individual must be ≥18 years old; coverage duration is 1 year.

    Prior Authorization

    Bimzelx — PA and 1‑year coverage; age restriction 18+

    BIMZELX prior authorization: approvals are for individuals aged 18 years or older with documentation meeting the AAD 2019 psoriasis criteria; coverage duration is 1 year.

    Prior Authorization

    Other listed specialty products — PA required (typical 1 year)

    Prior authorization is required for the many specialty products listed in this segment; the typical coverage duration is 1 year and product‑specific required information (age, diagnostics, biomarkers, prior therapy) is noted per product.

    Prior Authorization

    PA required for listed specialty products — prescriber restrictions may apply

    Prior authorization is required for the specialty products listed; coverage duration is commonly 1 year and prescriber or other restrictions may apply per product entry.

    Prior Authorization

    Carglumic acid — diagnostic criteria and continuation monitoring

    Carglumic acid prior authorization requires documentation of N‑acetylglutamate synthase (NAGS) deficiency for initial use (acute or chronic) or use as adjunctive therapy for PA/MA; continuation requires clinically significant improvement or stabilization in plasma ammonia.

    Prior Authorization

    Cosentyx — indication‑specific prior therapy documentation required

    Cosentyx prior authorization requires indication‑specific diagnostic documentation and prior‑therapy trials (e.g., phototherapy or systemic therapy for plaque psoriasis); continuation requires clinical improvement or stabilization.

    Prior Authorization

    Cresemba — inpatient initiation then outpatient continuation; prerequisite antifungal therapy required

    Cresemba (isavuconazonium) prior authorization requires documentation that therapy was initiated inpatient and is being continued outpatient when applicable, and documentation of prior antifungal therapy failure/intolerance or contraindication for specified indications; coverage duration is 1 year.

    Documentation Required

    Cresemba — document prior antifungal therapy or contraindication

    Cresemba prior authorization: document prior antifungal therapy or contraindication (e.g., voriconazole, amphotericin B) as required for the indication; PA and 1‑year duration apply.

    Prior Authorization

    Cystagon — prior authorization (1 year)

    Cystagon requires prior authorization; coverage duration is 1 year.

    Documentation Required

    Danziten — molecular testing (Ph and listed mutations) required

    Danziten prior authorization requires documentation of Philadelphia chromosome status and specific mutation testing (e.g., T315I, Y253H, E255K/V, F359V/C/I, G250E); coverage duration is 1 year.

    Prior Authorization

    Daraprim — leucovorin combination and indication documentation

    Daraprim (pyrimethamine) prior authorization requires use in combination with leucovorin and documentation of the treated indication (e.g., toxoplasmosis); coverage duration is 1 year.

    Denial Risk

    Darzalex FASPRO — exclusion if prior anti‑CD38 therapy received

    Darzalex FASPRO prior authorization requires that the member has not received prior treatment with daratumumab or another anti‑CD38 agent (an exclusion); coverage duration is 1 year.

    GLP and related agentsmixed
    OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PENINJECTOR 2 MG/3MLlisted product
    OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PENINJECTOR 4 MG/3MLlisted product
    OZEMPIC (2 MG/DOSE)listed product
    OZEMPIC ORAL TABLET 1.5 MG, 4 MG, 9 MGlisted product
    RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MGlisted product
    TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTORlisted product
    liraglutidelisted product
    Gomeklimixed
    GOMEKLI ORAL CAPSULE 1 MG, 2 MGlisted product
    GOMEKLI ORAL TABLET SOLUBLElisted product
    Hadlima (adalimumab biosimilar)mixed
    HADLIMA PUSHTOUCH SUBCUTANEOUS SOLUTION AUTOINJECTOR 40 MG/0.4ML, 40 MG/0.8MLlisted product
    HADLIMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML, 40 MG/0.8MLlisted product
    Hepsera (adefovir)mixed
    adefovir dipivoxillisted product
    Hernexeosmixed
    HERNEXEOSlisted product
    High Risk Medications (HRM) listmixed
    No codes listed
    Human Growth Hormonemixed
    NORDITROPIN FLEXPROhuman growth hormone product listed
    OMNITROPEhuman growth hormone product listed
    AYVAKIT platelet count key valuemixed
    ≥ 50 x 10^9/LPlatelet count threshold for AYVAKIT as listed
    Usage noteAsthma criterion requires prior 3-month trial of combination controller therapy per policy
    inv-158: SELENA-SLEDAI score for Benlysta — >= 6 (disease activity threshold)
    SELENA‑SLEDAI disease activity thresholdSELENA‑SLEDAI score ≥ 6 required to demonstrate active SLE at initiation of Benlysta
    Laboratory verificationSLE diagnosis must be supported by ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL
    Therapy contextActive disease must persist despite ≥30 days of corticosteroid, antimalarial, and/or immunosuppressant therapy
    inv-159: Psoriasis body surface area threshold — >= 3% BSA (or <3% with sensitive areas) per AAD 2019
    Psoriasis severity threshold>= 3% body surface area (BSA) OR <3% BSA involving sensitive/impact areas (per AAD 2019)
    Age requirementProduct entries reference age minima per indication (see product-specific blocks)
    DocumentationRequired medical information includes documented percent BSA or notation of sensitive/impactful area involvement
    inv-167: ENDARI age minimum — >= 5 years
    ENDARI minimum age>= 5 years
    Diagnostic requirementDiagnosis of sickle cell anemia defined as HbSS or HbS/β0‑thalassemia with ≥2 sickle cell crises in prior 12 months required for initial use
    inv-168: EMSAM age minimum — >= 18 years
    EMSAM minimum age>= 18 years
    Safety requirementIndividual must have no known contraindications to MAOI therapy
    inv-169: ENBREL age minimum (general) — adult and pediatric age minima by indication
    ENBREL general age minimaAdults ≥18 years; PsA and JIA: ≥2 years; plaque psoriasis: ≥4 years
    Severity/documentationPlaque psoriasis: BSA ≥3% or <3% with sensitive/impact areas per AAD 2019 required for initial use
    inv-170: FVC threshold for pirfenidone — >= 50%
    FVC threshold for pirfenidone>= 50% predicted FVC required for initial Esbriet (pirfenidone) use
    Diagnostic requirementIPF diagnosis must be supported by HRCT (with or without lung tissue sampling) and exclusion of other ILD causes
    inv-174: Hemoglobin A1c threshold — >= 6.5% (diabetes diagnostic criteria referenced for GLP agents)
    Hemoglobin A1c threshold>= 6.5% (one of the diabetes diagnostic criteria required for GLP‑1 agent coverage)
    Alternate diagnostic optionsFasting plasma glucose ≥126 mg/dL OR 2‑hour OGTT ≥200 mg/dL OR symptoms with random glucose ≥200 mg/dL acceptable alternatives
    inv-179: Gomekli NF1 BSA — BSA >= 0.40 m2
    Gomekli NF1 BSA requirementBody Surface Area (BSA) ≥ 0.40 m2 required for Gomekli coverage in NF1
    Coverage durationCoverage duration commonly listed as 1 year for Gomekli
    inv-180: Growth hormone stimulation test thresholds — GH response <10 ng/mL pediatrics; adults <=5 ng/mL (insulin) or <=4.1 ng/mL (arginine)
    Pediatric GH stimulation thresholdPeak GH response < 10 ng/mL on stimulation testing (subnormal) for pediatric GHD
    Adult GH stimulation thresholdsAdults: ≤ 5 ng/mL with insulin‑induced hypoglycemia OR ≤ 4.1 ng/mL with arginine (or alternative reconfirmation pathways)
    Testing protocol notePediatrics: subnormal defined as <10 ng/mL on two tests (or one provocative test with low IGF‑I) per policy
    inv-459: DIFICID (fidaxomicin) quantity limit — 30 days
    DIFICID quantity limitCoverage duration / quantity limit: 30 days
    IndicationsAll medically‑accepted indications documented; prior authorization required
    Initial approval: 6 months (selected indications); Continuation: 1 year
    Indication specificsInitial use requires indication‑specific diagnostic confirmation and prior therapy trials (e.g., eosinophils >=150 cells/µL for asthma)
    inv-462: Duragesic (fentanyl) — Initial 3 months; Maintenance 6 months; Cancer/Terminal/Palliative 1 Year
    Duragesic coverage durationsInitial: 3 months; Maintenance: 6 months; Cancer/Terminal/Palliative: 1 year
    Age restrictionProduct listing notes age ≥2 years for fentanyl patch use
    Initiation criteriaInitial use requires documentation of cancer/terminal/palliative pain or daily around‑the‑clock long‑acting opioid need and prior therapy criteria